Lenalidomide and pomalidomide potently interfere with induction of myeloid‐derived suppressor cells in multiple myeloma
Year: 2020
Type: article
Abstract: An increase in immunosuppressive myeloid-derived suppressor cells (MDSCs) is associated with disease progression and treatment resistance in multiple myeloma (MM). We investigated the mechanisms underlying MDSC induction, and sought to discover a strategy for prevention of MDSC induction in MM. Using a transwell co-culture system, four of nine examined human myeloma-derived cell lines (HMCLs) were potent in inducing monocytic (M)-MDSCs from normal peripheral blood mononuclear cells (PBMCs). As the results, we identified that secretion of C-C motif chemokine ligand 5 (CCL5) and macrophage migration inhibitory factor (MIF) by myeloma cells is a prerequisite for induction of MDSCs in MM. The immunomodulatory drug (IMiD) compounds, such as lenalidomide (LEN) and pomalidomide (POM), were identified as potent inhibitors of MDSC induction through bidirectional molecular effects of cereblon (CRBN)-dependent and -independent downregulation of CCL5 and MIF in myeloma cells; and downregulation of C-C motif chemokine receptor 5, a receptor for CCL5, and induction of interferon regulatory factor 8, a critical transcription factor for monocytic differentiation, in PBMCs. In the present study of the molecular mechanisms underlying MDSC induction, we identified a novel effect of LEN and POM of inhibiting MDSC induction via overlapping regulatory effects in myeloma cells and normal PBMCs.
Source: British Journal of Haematology
DOI: 10.1111/bjh.16881
Authors: Saeko Kuwahara‐Ota, Yuji Shimura, Christian Steinebach, Reiko Isa, Junko Yamaguchi, Daichi Nishiyama, Yuto Fujibayashi, Tomoko Takimoto‐Shimomura, Yoshimi Mizuno, Yayoi Matsumura‐Kimoto, Taku Tsukamoto, Yoshiaki Chinen, Tsutomu Kobayashi, Shigeo Horiike, Masafumi Taniwaki, Michael Gütschow, Junya Kuroda
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Awards: G2125753552, mir-17~92 cluster in mantle cell lymphoma, G3331013478, Drug discovery targeted against RSK2 in multiple myeloma, G3615670485, G368304172, G3796951135, 高齢者多発性骨髄腫患者に対する至適な分子標的療法と高齢者評価ツールの確立および治療効果と毒性に関するバイオマーカーの探索的研究, G4455731588, G5104421050, G6555758251, G6826071181, G7140004817, G7565344692, G8137634832, Molecular mechanisms underlying the induction of myeloid-derived suppressor cells in multiple myeloma, G999311716
OpenAlex ID: W3035813128
